[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f3vUbEgqG5VShb4YcDRQjtIbG2tm2jRAvrciQBXisVao":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":75,"rows":82},"Sichuan Baili Pharmaceutical Co., Ltd.",[4],113,false,108,26,20918,63,0,[14,17,20,23,26,29,32,35],{"name":15,"count":16},"Solid Tumor",23,{"name":18,"count":19},"Non-small Cell Lung Cancer",13,{"name":21,"count":22},"Breast Cancer",10,{"name":24,"count":25},"Head and Neck Squamous Cell Carcinoma",7,{"name":27,"count":28},"HER2-positive Breast Cancer",5,{"name":30,"count":31},"Solid Tumors",4,{"name":33,"count":34},"Nasopharyngeal Carcinoma",3,{"name":36,"count":34},"Urothelial Carcinoma",[38,43,47,51,54,57,60,64,67,71],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05020457","SI-B001 Combined With Chemotherapy in the Treatment of EGFR\u002FALK WT Recurrent or Metastatic NSCLC.","2025-12","SI-B001",{"nctId":44,"briefTitle":45,"date":41,"intervention":46},"NCT05627856","A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK\u002F T-cell Lymphoma, AITL, and Other NHL","GNC-038",{"nctId":48,"briefTitle":49,"date":41,"intervention":50},"NCT04606472","A Study of SI-B003, a PD-1\u002FCTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors","SI-B003",{"nctId":52,"briefTitle":53,"date":41,"intervention":42},"NCT05020769","SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.",{"nctId":55,"briefTitle":56,"date":41,"intervention":42},"NCT05044897","A Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in the Treatment of Recurrent and Metastatic HNSCC",{"nctId":58,"briefTitle":59,"date":41,"intervention":42},"NCT05022654","SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.",{"nctId":61,"briefTitle":62,"date":41,"intervention":63},"NCT05944978","A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies","GNC-035",{"nctId":65,"briefTitle":66,"date":41,"intervention":42},"NCT04603287","A Study of SI-B001, an EGFR\u002FHER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors",{"nctId":68,"briefTitle":69,"date":41,"intervention":70},"NCT05393427","A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors","BL-B01D1",{"nctId":72,"briefTitle":73,"date":41,"intervention":74},"NCT05949619","A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors","BL-M02D1",[76,77,78,79,80,81],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[83,466,632,732,784,818,852,886,912,938,982,1008,1034,1061,1083,1105,1127,1149,1171,1193,1215,1237,1259,1281,1303,1325,1343,1361,1379,1397,1415,1433,1451,1469,1487,1505,1523,1541,1559,1577,1636,1710,1748,1800,1834,1856,1878,1896,1914,1932,1950,1974,1992,2038,2074,2111,2141,2171,2200,2230,2252,2273,2296,2318,2346,2364,2382,2407],{"intervention":70,"totalTrials":84,"cells":85},38,{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":127,"PHASE3":321,"PHASE4":462,"NA":464},{"trials":87,"activeCount":12},[],{"trials":89,"activeCount":31,"soonestReadout":41},[90,102,110,118],{"nctId":91,"briefTitle":92,"status":93,"phases":94,"primaryCompletion":95,"completion":96,"start":97,"enrollment":98,"conditions":99,"interventions":101},"NCT05194982","A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor","RECRUITING",[77],"2026-12","2027-12","2021-11-29",570,[100],"Locally Advanced or Metastatic Solid Tumor",[70],{"nctId":103,"briefTitle":104,"status":93,"phases":105,"primaryCompletion":95,"completion":96,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT05470348","A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",[77],"2022-08-11",36,[21,15],[70],{"nctId":68,"briefTitle":69,"status":111,"phases":112,"primaryCompletion":41,"completion":41,"start":113,"enrollment":31,"conditions":114,"interventions":117},"ACTIVE_NOT_RECRUITING",[77],"2022-02-15",[115,116],"Locally Advanced or Metastatic Urinary Tumors","Other Solid Tumors",[70],{"nctId":119,"briefTitle":120,"status":93,"phases":121,"primaryCompletion":95,"completion":96,"start":122,"enrollment":123,"conditions":124,"interventions":126},"NCT05262491","A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor",[77],"2022-02-14",96,[125],"Gastrointestinal Tumor",[70],{"trials":128,"activeCount":320,"soonestReadout":253},[129,137,145,155,163,174,185,195,206,213,224,232,240,249,258,268,276,286,294,303,312],{"nctId":130,"briefTitle":131,"status":93,"phases":132,"primaryCompletion":95,"completion":96,"start":133,"enrollment":134,"conditions":135,"interventions":136},"NCT05965856","A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors",[78],"2023-12-11",52,[36,15],[70,50],{"nctId":138,"briefTitle":139,"status":93,"phases":140,"primaryCompletion":95,"completion":96,"start":141,"enrollment":142,"conditions":143,"interventions":144},"NCT06006169","A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",[78],"2023-10-20",186,[24],[70,50],{"nctId":146,"briefTitle":147,"status":93,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":134,"conditions":151,"interventions":153},"NCT06471205","A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer",[78],"2026-07","2024-08-02",[152],"Triple-negative Breast Cancer",[70,154],"PD-1 Monoclonal Antibody",{"nctId":156,"briefTitle":157,"status":93,"phases":158,"primaryCompletion":95,"completion":96,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT05956587","A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors",[78],"2024-01-29",121,[18,33],[70,50],{"nctId":164,"briefTitle":165,"status":93,"phases":166,"primaryCompletion":167,"completion":96,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT06986785","A Study of BL-B01D1 Combined With Lenvatinib in Patients With Advanced Hepatocellular Carcinoma",[78],"2027-05","2025-06-24",46,[171],"Advanced Hepatocellular Carcinoma",[70,173],"Lenvatinib",{"nctId":175,"briefTitle":176,"status":93,"phases":177,"primaryCompletion":95,"completion":96,"start":178,"enrollment":179,"conditions":180,"interventions":184},"NCT06008054","A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors",[78],"2023-11-16",376,[181,182,183],"Esophageal Cancer","Gastric Cancer","Colorectal Cancer",[50,70,154],{"nctId":186,"briefTitle":187,"status":111,"phases":188,"primaryCompletion":189,"completion":96,"start":190,"enrollment":191,"conditions":192,"interventions":194},"NCT06787664","A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma",[78],"2027-06","2025-01-16",27,[193],"Chordoma",[70],{"nctId":196,"briefTitle":197,"status":93,"phases":198,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},"NCT06437509","A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer",[78],"2026-06","2024-06-13",66,[203],"Extensive-stage Small-cell Lung Cancer",[70,205],"PD-1 monoclonal antibody",{"nctId":207,"briefTitle":208,"status":93,"phases":209,"primaryCompletion":199,"completion":199,"start":210,"enrollment":169,"conditions":211,"interventions":212},"NCT06437522","A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",[78],"2024-06-07",[24],[70,205],{"nctId":214,"briefTitle":215,"status":93,"phases":216,"primaryCompletion":167,"completion":96,"start":217,"enrollment":123,"conditions":218,"interventions":221},"NCT07054567","A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer",[78],"2025-08-21",[219,220],"Cervical Cancer","Endometrial Cancer",[70,222,223],"Pembrolizumab","Bevacizumab",{"nctId":225,"briefTitle":226,"status":93,"phases":227,"primaryCompletion":95,"completion":96,"start":228,"enrollment":229,"conditions":230,"interventions":231},"NCT06042894","A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer",[78],"2023-12-12",58,[21],[70,50],{"nctId":233,"briefTitle":234,"status":93,"phases":235,"primaryCompletion":167,"completion":96,"start":236,"enrollment":169,"conditions":237,"interventions":239},"NCT06978114","A Study of BL-B01D1+PD-1\u002FPD-L1 Monoclonal Antibody in Patients With Advanced Biliary Tract Cancer",[78],"2025-06-10",[238],"Advanced Biliary Tract Cancer",[70,222],{"nctId":241,"briefTitle":242,"status":93,"phases":243,"primaryCompletion":95,"completion":96,"start":244,"enrollment":245,"conditions":246,"interventions":248},"NCT05785039","A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors",[78],"2023-04-20",76,[247,15],"Urinary System Tumor",[70],{"nctId":250,"briefTitle":251,"status":93,"phases":252,"primaryCompletion":253,"completion":253,"start":254,"enrollment":134,"conditions":255,"interventions":256},"NCT06405425","A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma",[78],"2026-05","2024-05-29",[36],[70,257],"PD-1",{"nctId":259,"briefTitle":260,"status":111,"phases":261,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":266},"NCT05880706","A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer",[78],"2027-07","2023-07-19",198,[18],[70,267],"Osimertinib Mesylate",{"nctId":269,"briefTitle":270,"status":93,"phases":271,"primaryCompletion":95,"completion":96,"start":272,"enrollment":273,"conditions":274,"interventions":275},"NCT05990803","A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies",[78],"2023-11-06",130,[219],[70,50],{"nctId":277,"briefTitle":278,"status":93,"phases":279,"primaryCompletion":167,"completion":96,"start":280,"enrollment":281,"conditions":282,"interventions":284},"NCT06962787","A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer",[78],"2025-07-28",260,[283],"Renal Cancer",[70,285,173,222],"Axitinib",{"nctId":287,"briefTitle":288,"status":93,"phases":289,"primaryCompletion":95,"completion":96,"start":290,"enrollment":84,"conditions":291,"interventions":293},"NCT05803018","A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies",[77,78],"2023-06-25",[292,15],"Gynecological Malignant Tumor",[70],{"nctId":295,"briefTitle":296,"status":93,"phases":297,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":301,"interventions":302},"NCT06498986","A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer",[78],"2026-08","2024-07-31",40,[18],[70,267],{"nctId":304,"briefTitle":305,"status":93,"phases":306,"primaryCompletion":95,"completion":96,"start":307,"enrollment":308,"conditions":309,"interventions":311},"NCT05924841","A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer",[78],"2023-11-10",100,[310],"Small Cell Lung Cancer",[70,50],{"nctId":313,"briefTitle":314,"status":93,"phases":315,"primaryCompletion":149,"completion":149,"start":316,"enrollment":98,"conditions":317,"interventions":318},"NCT06475300","A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors",[78],"2024-06-25",[18,33,15],[70,154,319],"Pemetrexed Disodium",21,{"trials":322,"activeCount":19,"soonestReadout":253},[323,335,350,359,368,377,390,402,412,422,431,444,453],{"nctId":324,"briefTitle":325,"status":111,"phases":326,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":330,"interventions":331},"NCT06118333","A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)",[79],"2026-11","2023-12-04",386,[33],[70,332,333,334],"capecitabine","gemcitabine","docetaxel",{"nctId":336,"briefTitle":337,"status":338,"phases":339,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":345},"NCT07554456","A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)","NOT_YET_RECRUITING",[78,79],"2028-12","2026-04",90,[344],"Esophageal Squamous Cell Carcinoma",[70,346,347,348,349],"Tislelizumab","5-Fluorouracil","Cisplatin","Paclitaxel",{"nctId":351,"briefTitle":352,"status":93,"phases":353,"primaryCompletion":340,"completion":340,"start":354,"enrollment":355,"conditions":356,"interventions":357},"NCT06838273","A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)",[79],"2025-02-24",720,[18],[70,358,358],"Osimertinib",{"nctId":360,"briefTitle":361,"status":111,"phases":362,"primaryCompletion":95,"completion":95,"start":363,"enrollment":364,"conditions":365,"interventions":366},"NCT06500026","A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)",[79],"2024-08-07",722,[310],[70,367],"Topotecan",{"nctId":369,"briefTitle":370,"status":111,"phases":371,"primaryCompletion":95,"completion":95,"start":372,"enrollment":373,"conditions":374,"interventions":375},"NCT06382129","A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)",[79],"2024-05-17",698,[18],[70,376],"Docetaxel",{"nctId":378,"briefTitle":379,"status":111,"phases":380,"primaryCompletion":199,"completion":199,"start":381,"enrollment":382,"conditions":383,"interventions":385},"NCT06382142","A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)",[79],"2024-06-21",418,[384],"Triple-Negative Breast Cancer",[70,386,387,388,389],"Eribulin","Vinorelbine","Gemcitabine","Capecitabine",{"nctId":391,"briefTitle":392,"status":93,"phases":393,"primaryCompletion":189,"completion":96,"start":394,"enrollment":395,"conditions":396,"interventions":400},"NCT06994195","A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)",[79],"2025-08-04",384,[397,398,399],"Epithelial Ovarian Cancer","Fallopian Tube Cancer","Primary Peritoneal Cancer",[70,401],"Liposomal doxorubicin, Paclitaxel or Topotecan",{"nctId":403,"briefTitle":404,"status":111,"phases":405,"primaryCompletion":253,"completion":253,"start":406,"enrollment":407,"conditions":408,"interventions":409},"NCT06304974","A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)",[79],"2024-03-19",497,[344],[70,410,411,334],"Irinotecan","paclitaxel",{"nctId":413,"briefTitle":414,"status":338,"phases":415,"primaryCompletion":416,"completion":416,"start":341,"enrollment":417,"conditions":418,"interventions":419},"NCT07502300","A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)",[79],"2029-12",562,[203],[70,346,420,421],"Carboplatin","Etoposide",{"nctId":423,"briefTitle":424,"status":111,"phases":425,"primaryCompletion":253,"completion":253,"start":426,"enrollment":427,"conditions":428,"interventions":430},"NCT06343948","A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)",[79],"2024-04-24",383,[429],"HR+HER2- Breast Cancer",[70,386,387,388,389],{"nctId":432,"briefTitle":433,"status":338,"phases":434,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":436,"interventions":438},"NCT07582315","A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1\u002FPD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)",[79],538,[437],"Biliary Tract Cancer",[70,439,440,441,442,443,389],"Oxaliplatin","Calcium levofolinate","Fluorouracil","Irinotecan Hydrochloride Liposome","Irinotecan Hydrochloride",{"nctId":445,"briefTitle":446,"status":111,"phases":447,"primaryCompletion":253,"completion":253,"start":448,"enrollment":449,"conditions":450,"interventions":451},"NCT06382116","A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01)",[79],"2024-05-22",432,[18],[70,452],"Pemetrexed+Cisplatin or Carboplatin",{"nctId":454,"briefTitle":455,"status":93,"phases":456,"primaryCompletion":189,"completion":96,"start":457,"enrollment":458,"conditions":459,"interventions":460},"NCT06857175","A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01)",[79],"2025-03-25",508,[36],[70,461],"Docetaxel or Paclitaxel",{"trials":463,"activeCount":12},[],{"trials":465,"activeCount":12},[],{"intervention":467,"totalTrials":468,"cells":469},"BL-M07D1",17,{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":490,"PHASE3":545,"PHASE4":628,"NA":630},{"trials":471,"activeCount":12},[],{"trials":473,"activeCount":489,"soonestReadout":95},[474,482],{"nctId":475,"briefTitle":476,"status":93,"phases":477,"primaryCompletion":95,"completion":96,"start":478,"enrollment":9,"conditions":479,"interventions":481},"NCT05631964","Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors",[77],"2023-01-05",[480,116],"Locally Advanced or Metastatic Digestive Tract Tumors",[467],{"nctId":483,"briefTitle":484,"status":93,"phases":485,"primaryCompletion":95,"completion":96,"start":486,"enrollment":9,"conditions":487,"interventions":488},"NCT05461768","A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive\u002FLow Expression Breast Cancer and Other Solid Tumors",[77],"2022-08-09",[21,100],[467],2,{"trials":491,"activeCount":544,"soonestReadout":341},[492,501,510,519,526,535],{"nctId":493,"briefTitle":494,"status":111,"phases":495,"primaryCompletion":95,"completion":95,"start":496,"enrollment":497,"conditions":498,"interventions":499},"NCT06445400","A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer",[78],"2024-06-19",83,[27],[467,500,376],"Pertuzumab",{"nctId":502,"briefTitle":503,"status":93,"phases":504,"primaryCompletion":505,"completion":505,"start":506,"enrollment":300,"conditions":507,"interventions":509},"NCT06423885","A Study of BL-M07D1 Combination Therapy in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma",[78],"2026-10","2024-12-24",[508],"HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma",[467,205],{"nctId":511,"briefTitle":512,"status":93,"phases":513,"primaryCompletion":95,"completion":96,"start":514,"enrollment":515,"conditions":516,"interventions":518},"NCT06131450","A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies",[77,78],"2024-02-29",138,[517],"Gynecological Malignancies",[467],{"nctId":520,"briefTitle":521,"status":93,"phases":522,"primaryCompletion":341,"completion":341,"start":426,"enrollment":523,"conditions":524,"interventions":525},"NCT06114511","A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer",[77,78],98,[18],[467],{"nctId":527,"briefTitle":528,"status":93,"phases":529,"primaryCompletion":96,"completion":96,"start":530,"enrollment":531,"conditions":532,"interventions":534},"NCT07264816","A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC",[78],"2026-02-03",80,[533],"Non-squamous Non-small Cell Lung Cancer",[467,222],{"nctId":536,"briefTitle":537,"status":93,"phases":538,"primaryCompletion":95,"completion":95,"start":539,"enrollment":540,"conditions":541,"interventions":543},"NCT06031584","A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive\u002FLow-expressing Urinary and Gastrointestinal Tumors",[77,78],"2024-01-19",42,[542],"Her2-positive\u002FLow-expression Urinary and Digestive Tract Tumors",[467],6,{"trials":546,"activeCount":627,"soonestReadout":253},[547,556,563,574,583,593,601,609,617],{"nctId":548,"briefTitle":549,"status":111,"phases":550,"primaryCompletion":253,"completion":253,"start":551,"enrollment":552,"conditions":553,"interventions":554},"NCT06316531","A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer",[79],"2024-05-08",274,[27],[467,555],"T-DM1",{"nctId":557,"briefTitle":558,"status":338,"phases":559,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":561,"interventions":562},"NCT07606599","A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure",[79],398,[437],[467,439,440,441,442,443,389],{"nctId":564,"briefTitle":565,"status":93,"phases":566,"primaryCompletion":189,"completion":189,"start":567,"enrollment":568,"conditions":569,"interventions":572},"NCT07152405","A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma",[79],"2025-09-24",490,[570,571],"Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma",[467,573],"Investigator's choice of chemotherapy",{"nctId":575,"briefTitle":576,"status":93,"phases":577,"primaryCompletion":96,"completion":96,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT07178795","A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC",[79],"2025-09-29",440,[533],[467,222,582,420,348],"Pemetrexed",{"nctId":584,"briefTitle":585,"status":93,"phases":586,"primaryCompletion":167,"completion":96,"start":587,"enrollment":588,"conditions":589,"interventions":591},"NCT06957886","A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent\u002FMetastatic Breast Cancer",[79],"2025-05-15",566,[590],"HER2-low Breast Cancer",[467,592],"Capecitabine, Eribulin, Gemcitabine, Paclitaxel, or Albumin paclitaxel",{"nctId":594,"briefTitle":595,"status":93,"phases":596,"primaryCompletion":340,"completion":340,"start":597,"enrollment":598,"conditions":599,"interventions":600},"NCT06891833","A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer",[78,79],"2025-06-05",120,[27],[467,500],{"nctId":602,"briefTitle":603,"status":338,"phases":604,"primaryCompletion":416,"completion":416,"start":341,"enrollment":605,"conditions":606,"interventions":607},"NCT07518173","A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer",[79],596,[27],[467,500,608,376],"Trastuzumab",{"nctId":610,"briefTitle":611,"status":338,"phases":612,"primaryCompletion":340,"completion":340,"start":341,"enrollment":613,"conditions":614,"interventions":615},"NCT07545460","A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer",[79],404,[397,398,399],[467,616,349,367],"Liposomal Doxorubicin",{"nctId":618,"briefTitle":619,"status":93,"phases":620,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":626},"NCT06830889","A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy",[79],"2031-10","2031-12","2025-06-03",1450,[27],[467,555],9,{"trials":629,"activeCount":12},[],{"trials":631,"activeCount":12},[],{"intervention":42,"totalTrials":633,"cells":634},11,{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":647,"PHASE3":710,"PHASE4":728,"NA":730},{"trials":636,"activeCount":12},[],{"trials":638,"activeCount":646,"soonestReadout":41},[639],{"nctId":65,"briefTitle":66,"status":111,"phases":640,"primaryCompletion":41,"completion":41,"start":641,"enrollment":642,"conditions":643,"interventions":645},[77],"2020-04-17",60,[644],"Locally Advanced or Metastatic Epithelial Tumor",[42],1,{"trials":648,"activeCount":25,"soonestReadout":41},[649,657,662,669,676,684,691,699],{"nctId":39,"briefTitle":40,"status":111,"phases":650,"primaryCompletion":41,"completion":41,"start":651,"enrollment":652,"conditions":653,"interventions":655},[78],"2021-12-07",69,[654],"Non Small Cell Lung Cancer",[42,656,376],"AP or TP",{"nctId":55,"briefTitle":56,"status":111,"phases":658,"primaryCompletion":41,"completion":41,"start":659,"enrollment":633,"conditions":660,"interventions":661},[78],"2021-10-20",[24],[42],{"nctId":58,"briefTitle":59,"status":111,"phases":663,"primaryCompletion":41,"completion":41,"start":664,"enrollment":665,"conditions":666,"interventions":668},[78],"2021-12-13",22,[667],"Esophageal Squamous Cell Carcinomas",[42,410],{"nctId":670,"briefTitle":671,"status":93,"phases":672,"primaryCompletion":327,"completion":327,"start":673,"enrollment":642,"conditions":674,"interventions":675},"NCT06668961","A Study of SI-B001+SI-B003 Combined With Platinum-based Chemotherapy as First-line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[78],"2024-11-07",[24],[42,50],{"nctId":677,"briefTitle":678,"status":93,"phases":679,"primaryCompletion":95,"completion":96,"start":680,"enrollment":681,"conditions":682,"interventions":683},"NCT05949606","A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer",[77,78],"2023-10-30",160,[18],[42,50],{"nctId":685,"briefTitle":686,"status":111,"phases":687,"primaryCompletion":41,"completion":41,"start":688,"enrollment":540,"conditions":689,"interventions":690},"NCT05054439","A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC",[78],"2021-12-22",[24],[42,349],{"nctId":692,"briefTitle":693,"status":93,"phases":694,"primaryCompletion":95,"completion":96,"start":695,"enrollment":273,"conditions":696,"interventions":698},"NCT05668858","A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma",[77,78],"2023-02-10",[697],"Squamous Cell Carcinoma of Head and Neck",[42,50],{"nctId":700,"briefTitle":701,"status":702,"phases":703,"primaryCompletion":704,"completion":704,"start":705,"enrollment":25,"conditions":706,"interventions":707},"NCT05039944","SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies","TERMINATED",[78],"2022-06-06","2021-11-30",[183],[42,410,708,709],"FOLFIRI Protocol","FOLFOX Protocol",{"trials":711,"activeCount":489,"soonestReadout":41},[712,722],{"nctId":713,"briefTitle":714,"status":111,"phases":715,"primaryCompletion":149,"completion":149,"start":716,"enrollment":717,"conditions":718,"interventions":721},"NCT05943795","A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma",[79],"2023-07-14",589,[719,720],"Non-small Cell Lung Adenocarcinoma","Squamous Cell Carcinoma of Lung",[42,376],{"nctId":52,"briefTitle":53,"status":111,"phases":723,"primaryCompletion":41,"completion":41,"start":724,"enrollment":725,"conditions":726,"interventions":727},[78,79],"2022-01-06",14,[18],[42,358],{"trials":729,"activeCount":12},[],{"trials":731,"activeCount":12},[],{"intervention":376,"totalTrials":733,"cells":734},8,{"EARLY_PHASE1":735,"PHASE1":737,"PHASE2":739,"PHASE3":749,"PHASE4":780,"NA":782},{"trials":736,"activeCount":12},[],{"trials":738,"activeCount":12},[],{"trials":740,"activeCount":489,"soonestReadout":41},[741,745],{"nctId":39,"briefTitle":40,"status":111,"phases":742,"primaryCompletion":41,"completion":41,"start":651,"enrollment":652,"conditions":743,"interventions":744},[78],[654],[42,656,376],{"nctId":493,"briefTitle":494,"status":111,"phases":746,"primaryCompletion":95,"completion":95,"start":496,"enrollment":497,"conditions":747,"interventions":748},[78],[27],[467,500,376],{"trials":750,"activeCount":544,"soonestReadout":253},[751,755,759,763,767,776],{"nctId":324,"briefTitle":325,"status":111,"phases":752,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":753,"interventions":754},[79],[33],[70,332,333,334],{"nctId":713,"briefTitle":714,"status":111,"phases":756,"primaryCompletion":149,"completion":149,"start":716,"enrollment":717,"conditions":757,"interventions":758},[79],[719,720],[42,376],{"nctId":369,"briefTitle":370,"status":111,"phases":760,"primaryCompletion":95,"completion":95,"start":372,"enrollment":373,"conditions":761,"interventions":762},[79],[18],[70,376],{"nctId":403,"briefTitle":404,"status":111,"phases":764,"primaryCompletion":253,"completion":253,"start":406,"enrollment":407,"conditions":765,"interventions":766},[79],[344],[70,410,411,334],{"nctId":768,"briefTitle":769,"status":338,"phases":770,"primaryCompletion":416,"completion":416,"start":341,"enrollment":771,"conditions":772,"interventions":773},"NCT07518147","A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC\u002FGEJC) Who Have Received Prior First-Line Treatment",[79],438,[182,571],[774,349,376,775],"BL-M05D1","Irinotecan hydrochloride",{"nctId":602,"briefTitle":603,"status":338,"phases":777,"primaryCompletion":416,"completion":416,"start":341,"enrollment":605,"conditions":778,"interventions":779},[79],[27],[467,500,608,376],{"trials":781,"activeCount":12},[],{"trials":783,"activeCount":12},[],{"intervention":389,"totalTrials":28,"cells":785},{"EARLY_PHASE1":786,"PHASE1":788,"PHASE2":790,"PHASE3":792,"PHASE4":814,"NA":816},{"trials":787,"activeCount":12},[],{"trials":789,"activeCount":12},[],{"trials":791,"activeCount":12},[],{"trials":793,"activeCount":28,"soonestReadout":253},[794,798,802,806,810],{"nctId":324,"briefTitle":325,"status":111,"phases":795,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":796,"interventions":797},[79],[33],[70,332,333,334],{"nctId":557,"briefTitle":558,"status":338,"phases":799,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":800,"interventions":801},[79],[437],[467,439,440,441,442,443,389],{"nctId":378,"briefTitle":379,"status":111,"phases":803,"primaryCompletion":199,"completion":199,"start":381,"enrollment":382,"conditions":804,"interventions":805},[79],[384],[70,386,387,388,389],{"nctId":423,"briefTitle":424,"status":111,"phases":807,"primaryCompletion":253,"completion":253,"start":426,"enrollment":427,"conditions":808,"interventions":809},[79],[429],[70,386,387,388,389],{"nctId":432,"briefTitle":433,"status":338,"phases":811,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":812,"interventions":813},[79],[437],[70,439,440,441,442,443,389],{"trials":815,"activeCount":12},[],{"trials":817,"activeCount":12},[],{"intervention":349,"totalTrials":28,"cells":819},{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":830,"PHASE4":848,"NA":850},{"trials":821,"activeCount":12},[],{"trials":823,"activeCount":12},[],{"trials":825,"activeCount":646,"soonestReadout":41},[826],{"nctId":685,"briefTitle":686,"status":111,"phases":827,"primaryCompletion":41,"completion":41,"start":688,"enrollment":540,"conditions":828,"interventions":829},[78],[24],[42,349],{"trials":831,"activeCount":31,"soonestReadout":253},[832,836,840,844],{"nctId":336,"briefTitle":337,"status":338,"phases":833,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":834,"interventions":835},[78,79],[344],[70,346,347,348,349],{"nctId":403,"briefTitle":404,"status":111,"phases":837,"primaryCompletion":253,"completion":253,"start":406,"enrollment":407,"conditions":838,"interventions":839},[79],[344],[70,410,411,334],{"nctId":768,"briefTitle":769,"status":338,"phases":841,"primaryCompletion":416,"completion":416,"start":341,"enrollment":771,"conditions":842,"interventions":843},[79],[182,571],[774,349,376,775],{"nctId":610,"briefTitle":611,"status":338,"phases":845,"primaryCompletion":340,"completion":340,"start":341,"enrollment":613,"conditions":846,"interventions":847},[79],[397,398,399],[467,616,349,367],{"trials":849,"activeCount":12},[],{"trials":851,"activeCount":12},[],{"intervention":222,"totalTrials":28,"cells":853},{"EARLY_PHASE1":854,"PHASE1":856,"PHASE2":858,"PHASE3":876,"PHASE4":882,"NA":884},{"trials":855,"activeCount":12},[],{"trials":857,"activeCount":12},[],{"trials":859,"activeCount":31,"soonestReadout":167},[860,864,868,872],{"nctId":214,"briefTitle":215,"status":93,"phases":861,"primaryCompletion":167,"completion":96,"start":217,"enrollment":123,"conditions":862,"interventions":863},[78],[219,220],[70,222,223],{"nctId":233,"briefTitle":234,"status":93,"phases":865,"primaryCompletion":167,"completion":96,"start":236,"enrollment":169,"conditions":866,"interventions":867},[78],[238],[70,222],{"nctId":527,"briefTitle":528,"status":93,"phases":869,"primaryCompletion":96,"completion":96,"start":530,"enrollment":531,"conditions":870,"interventions":871},[78],[533],[467,222],{"nctId":277,"briefTitle":278,"status":93,"phases":873,"primaryCompletion":167,"completion":96,"start":280,"enrollment":281,"conditions":874,"interventions":875},[78],[283],[70,285,173,222],{"trials":877,"activeCount":646,"soonestReadout":96},[878],{"nctId":575,"briefTitle":576,"status":93,"phases":879,"primaryCompletion":96,"completion":96,"start":578,"enrollment":579,"conditions":880,"interventions":881},[79],[533],[467,222,582,420,348],{"trials":883,"activeCount":12},[],{"trials":885,"activeCount":12},[],{"intervention":388,"totalTrials":34,"cells":887},{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":908,"NA":910},{"trials":889,"activeCount":12},[],{"trials":891,"activeCount":12},[],{"trials":893,"activeCount":12},[],{"trials":895,"activeCount":34,"soonestReadout":253},[896,900,904],{"nctId":324,"briefTitle":325,"status":111,"phases":897,"primaryCompletion":327,"completion":327,"start":328,"enrollment":329,"conditions":898,"interventions":899},[79],[33],[70,332,333,334],{"nctId":378,"briefTitle":379,"status":111,"phases":901,"primaryCompletion":199,"completion":199,"start":381,"enrollment":382,"conditions":902,"interventions":903},[79],[384],[70,386,387,388,389],{"nctId":423,"briefTitle":424,"status":111,"phases":905,"primaryCompletion":253,"completion":253,"start":426,"enrollment":427,"conditions":906,"interventions":907},[79],[429],[70,386,387,388,389],{"trials":909,"activeCount":12},[],{"trials":911,"activeCount":12},[],{"intervention":500,"totalTrials":34,"cells":913},{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":924,"PHASE4":934,"NA":936},{"trials":915,"activeCount":12},[],{"trials":917,"activeCount":12},[],{"trials":919,"activeCount":646,"soonestReadout":95},[920],{"nctId":493,"briefTitle":494,"status":111,"phases":921,"primaryCompletion":95,"completion":95,"start":496,"enrollment":497,"conditions":922,"interventions":923},[78],[27],[467,500,376],{"trials":925,"activeCount":489,"soonestReadout":340},[926,930],{"nctId":594,"briefTitle":595,"status":93,"phases":927,"primaryCompletion":340,"completion":340,"start":597,"enrollment":598,"conditions":928,"interventions":929},[78,79],[27],[467,500],{"nctId":602,"briefTitle":603,"status":338,"phases":931,"primaryCompletion":416,"completion":416,"start":341,"enrollment":605,"conditions":932,"interventions":933},[79],[27],[467,500,608,376],{"trials":935,"activeCount":12},[],{"trials":937,"activeCount":12},[],{"intervention":939,"totalTrials":34,"cells":940},"BL-M11D1",{"EARLY_PHASE1":941,"PHASE1":943,"PHASE2":953,"PHASE3":963,"PHASE4":978,"NA":980},{"trials":942,"activeCount":12},[],{"trials":944,"activeCount":646,"soonestReadout":95},[945],{"nctId":946,"briefTitle":947,"status":93,"phases":948,"primaryCompletion":95,"completion":96,"start":949,"enrollment":273,"conditions":950,"interventions":952},"NCT05924750","A Study of BL-M11D1 in Patients With Relapsed\u002FRefractory Acute Myeloid Leukemia",[77],"2023-08-02",[951],"Relapsed\u002FRefractory Acute Myeloid Leukemia (R\u002FR AML)",[939],{"trials":954,"activeCount":646,"soonestReadout":340},[955],{"nctId":956,"briefTitle":957,"status":338,"phases":958,"primaryCompletion":340,"completion":340,"start":253,"enrollment":959,"conditions":960,"interventions":962},"NCT07591168","A Study of BL-M11D1 in Patients With Relapsed\u002FRefractory Myelodysplastic Syndromes",[77,78],92,[961],"Myelodysplastic Syndromes",[939],{"trials":964,"activeCount":646,"soonestReadout":96},[965],{"nctId":966,"briefTitle":967,"status":338,"phases":968,"primaryCompletion":96,"completion":96,"start":969,"enrollment":970,"conditions":971,"interventions":973},"NCT07255872","A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia",[78,79],"2026-03",216,[972],"Acute Myeloid Leukemia",[939,974,975,976,977],"Cytarabine","Daunorubicin","Venetoclax","Azacitidine",{"trials":979,"activeCount":12},[],{"trials":981,"activeCount":12},[],{"intervention":443,"totalTrials":34,"cells":983},{"EARLY_PHASE1":984,"PHASE1":986,"PHASE2":988,"PHASE3":990,"PHASE4":1004,"NA":1006},{"trials":985,"activeCount":12},[],{"trials":987,"activeCount":12},[],{"trials":989,"activeCount":12},[],{"trials":991,"activeCount":34,"soonestReadout":340},[992,996,1000],{"nctId":557,"briefTitle":558,"status":338,"phases":993,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":994,"interventions":995},[79],[437],[467,439,440,441,442,443,389],{"nctId":768,"briefTitle":769,"status":338,"phases":997,"primaryCompletion":416,"completion":416,"start":341,"enrollment":771,"conditions":998,"interventions":999},[79],[182,571],[774,349,376,775],{"nctId":432,"briefTitle":433,"status":338,"phases":1001,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":1002,"interventions":1003},[79],[437],[70,439,440,441,442,443,389],{"trials":1005,"activeCount":12},[],{"trials":1007,"activeCount":12},[],{"intervention":410,"totalTrials":34,"cells":1009},{"EARLY_PHASE1":1010,"PHASE1":1012,"PHASE2":1014,"PHASE3":1024,"PHASE4":1030,"NA":1032},{"trials":1011,"activeCount":12},[],{"trials":1013,"activeCount":12},[],{"trials":1015,"activeCount":646,"soonestReadout":41},[1016,1020],{"nctId":58,"briefTitle":59,"status":111,"phases":1017,"primaryCompletion":41,"completion":41,"start":664,"enrollment":665,"conditions":1018,"interventions":1019},[78],[667],[42,410],{"nctId":700,"briefTitle":701,"status":702,"phases":1021,"primaryCompletion":704,"completion":704,"start":705,"enrollment":25,"conditions":1022,"interventions":1023},[78],[183],[42,410,708,709],{"trials":1025,"activeCount":646,"soonestReadout":253},[1026],{"nctId":403,"briefTitle":404,"status":111,"phases":1027,"primaryCompletion":253,"completion":253,"start":406,"enrollment":407,"conditions":1028,"interventions":1029},[79],[344],[70,410,411,334],{"trials":1031,"activeCount":12},[],{"trials":1033,"activeCount":12},[],{"intervention":774,"totalTrials":489,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1049,"PHASE3":1051,"PHASE4":1057,"NA":1059},{"trials":1037,"activeCount":12},[],{"trials":1039,"activeCount":646,"soonestReadout":253},[1040],{"nctId":1041,"briefTitle":1042,"status":93,"phases":1043,"primaryCompletion":253,"completion":253,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1048},"NCT06349811","A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors",[77],"2024-04-19",30,[1047],"Locally Advanced or Metastatic Solid Tumors",[774],{"trials":1050,"activeCount":12},[],{"trials":1052,"activeCount":646,"soonestReadout":416},[1053],{"nctId":768,"briefTitle":769,"status":338,"phases":1054,"primaryCompletion":416,"completion":416,"start":341,"enrollment":771,"conditions":1055,"interventions":1056},[79],[182,571],[774,349,376,775],{"trials":1058,"activeCount":12},[],{"trials":1060,"activeCount":12},[],{"intervention":346,"totalTrials":489,"cells":1062},{"EARLY_PHASE1":1063,"PHASE1":1065,"PHASE2":1067,"PHASE3":1069,"PHASE4":1079,"NA":1081},{"trials":1064,"activeCount":12},[],{"trials":1066,"activeCount":12},[],{"trials":1068,"activeCount":12},[],{"trials":1070,"activeCount":489,"soonestReadout":340},[1071,1075],{"nctId":336,"briefTitle":337,"status":338,"phases":1072,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":1073,"interventions":1074},[78,79],[344],[70,346,347,348,349],{"nctId":413,"briefTitle":414,"status":338,"phases":1076,"primaryCompletion":416,"completion":416,"start":341,"enrollment":417,"conditions":1077,"interventions":1078},[79],[203],[70,346,420,421],{"trials":1080,"activeCount":12},[],{"trials":1082,"activeCount":12},[],{"intervention":348,"totalTrials":489,"cells":1084},{"EARLY_PHASE1":1085,"PHASE1":1087,"PHASE2":1089,"PHASE3":1091,"PHASE4":1101,"NA":1103},{"trials":1086,"activeCount":12},[],{"trials":1088,"activeCount":12},[],{"trials":1090,"activeCount":12},[],{"trials":1092,"activeCount":489,"soonestReadout":96},[1093,1097],{"nctId":336,"briefTitle":337,"status":338,"phases":1094,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":1095,"interventions":1096},[78,79],[344],[70,346,347,348,349],{"nctId":575,"briefTitle":576,"status":93,"phases":1098,"primaryCompletion":96,"completion":96,"start":578,"enrollment":579,"conditions":1099,"interventions":1100},[79],[533],[467,222,582,420,348],{"trials":1102,"activeCount":12},[],{"trials":1104,"activeCount":12},[],{"intervention":555,"totalTrials":489,"cells":1106},{"EARLY_PHASE1":1107,"PHASE1":1109,"PHASE2":1111,"PHASE3":1113,"PHASE4":1123,"NA":1125},{"trials":1108,"activeCount":12},[],{"trials":1110,"activeCount":12},[],{"trials":1112,"activeCount":12},[],{"trials":1114,"activeCount":489,"soonestReadout":253},[1115,1119],{"nctId":548,"briefTitle":549,"status":111,"phases":1116,"primaryCompletion":253,"completion":253,"start":551,"enrollment":552,"conditions":1117,"interventions":1118},[79],[27],[467,555],{"nctId":618,"briefTitle":619,"status":93,"phases":1120,"primaryCompletion":621,"completion":622,"start":623,"enrollment":624,"conditions":1121,"interventions":1122},[79],[27],[467,555],{"trials":1124,"activeCount":12},[],{"trials":1126,"activeCount":12},[],{"intervention":358,"totalTrials":489,"cells":1128},{"EARLY_PHASE1":1129,"PHASE1":1131,"PHASE2":1133,"PHASE3":1135,"PHASE4":1145,"NA":1147},{"trials":1130,"activeCount":12},[],{"trials":1132,"activeCount":12},[],{"trials":1134,"activeCount":12},[],{"trials":1136,"activeCount":489,"soonestReadout":41},[1137,1141],{"nctId":351,"briefTitle":352,"status":93,"phases":1138,"primaryCompletion":340,"completion":340,"start":354,"enrollment":355,"conditions":1139,"interventions":1140},[79],[18],[70,358,358],{"nctId":52,"briefTitle":53,"status":111,"phases":1142,"primaryCompletion":41,"completion":41,"start":724,"enrollment":725,"conditions":1143,"interventions":1144},[78,79],[18],[42,358],{"trials":1146,"activeCount":12},[],{"trials":1148,"activeCount":12},[],{"intervention":367,"totalTrials":489,"cells":1150},{"EARLY_PHASE1":1151,"PHASE1":1153,"PHASE2":1155,"PHASE3":1157,"PHASE4":1167,"NA":1169},{"trials":1152,"activeCount":12},[],{"trials":1154,"activeCount":12},[],{"trials":1156,"activeCount":12},[],{"trials":1158,"activeCount":489,"soonestReadout":95},[1159,1163],{"nctId":360,"briefTitle":361,"status":111,"phases":1160,"primaryCompletion":95,"completion":95,"start":363,"enrollment":364,"conditions":1161,"interventions":1162},[79],[310],[70,367],{"nctId":610,"briefTitle":611,"status":338,"phases":1164,"primaryCompletion":340,"completion":340,"start":341,"enrollment":613,"conditions":1165,"interventions":1166},[79],[397,398,399],[467,616,349,367],{"trials":1168,"activeCount":12},[],{"trials":1170,"activeCount":12},[],{"intervention":439,"totalTrials":489,"cells":1172},{"EARLY_PHASE1":1173,"PHASE1":1175,"PHASE2":1177,"PHASE3":1179,"PHASE4":1189,"NA":1191},{"trials":1174,"activeCount":12},[],{"trials":1176,"activeCount":12},[],{"trials":1178,"activeCount":12},[],{"trials":1180,"activeCount":489,"soonestReadout":340},[1181,1185],{"nctId":557,"briefTitle":558,"status":338,"phases":1182,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":1183,"interventions":1184},[79],[437],[467,439,440,441,442,443,389],{"nctId":432,"briefTitle":433,"status":338,"phases":1186,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":1187,"interventions":1188},[79],[437],[70,439,440,441,442,443,389],{"trials":1190,"activeCount":12},[],{"trials":1192,"activeCount":12},[],{"intervention":440,"totalTrials":489,"cells":1194},{"EARLY_PHASE1":1195,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1211,"NA":1213},{"trials":1196,"activeCount":12},[],{"trials":1198,"activeCount":12},[],{"trials":1200,"activeCount":12},[],{"trials":1202,"activeCount":489,"soonestReadout":340},[1203,1207],{"nctId":557,"briefTitle":558,"status":338,"phases":1204,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":1205,"interventions":1206},[79],[437],[467,439,440,441,442,443,389],{"nctId":432,"briefTitle":433,"status":338,"phases":1208,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":1209,"interventions":1210},[79],[437],[70,439,440,441,442,443,389],{"trials":1212,"activeCount":12},[],{"trials":1214,"activeCount":12},[],{"intervention":441,"totalTrials":489,"cells":1216},{"EARLY_PHASE1":1217,"PHASE1":1219,"PHASE2":1221,"PHASE3":1223,"PHASE4":1233,"NA":1235},{"trials":1218,"activeCount":12},[],{"trials":1220,"activeCount":12},[],{"trials":1222,"activeCount":12},[],{"trials":1224,"activeCount":489,"soonestReadout":340},[1225,1229],{"nctId":557,"briefTitle":558,"status":338,"phases":1226,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":1227,"interventions":1228},[79],[437],[467,439,440,441,442,443,389],{"nctId":432,"briefTitle":433,"status":338,"phases":1230,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":1231,"interventions":1232},[79],[437],[70,439,440,441,442,443,389],{"trials":1234,"activeCount":12},[],{"trials":1236,"activeCount":12},[],{"intervention":442,"totalTrials":489,"cells":1238},{"EARLY_PHASE1":1239,"PHASE1":1241,"PHASE2":1243,"PHASE3":1245,"PHASE4":1255,"NA":1257},{"trials":1240,"activeCount":12},[],{"trials":1242,"activeCount":12},[],{"trials":1244,"activeCount":12},[],{"trials":1246,"activeCount":489,"soonestReadout":340},[1247,1251],{"nctId":557,"briefTitle":558,"status":338,"phases":1248,"primaryCompletion":340,"completion":340,"start":253,"enrollment":560,"conditions":1249,"interventions":1250},[79],[437],[467,439,440,441,442,443,389],{"nctId":432,"briefTitle":433,"status":338,"phases":1252,"primaryCompletion":340,"completion":340,"start":253,"enrollment":435,"conditions":1253,"interventions":1254},[79],[437],[70,439,440,441,442,443,389],{"trials":1256,"activeCount":12},[],{"trials":1258,"activeCount":12},[],{"intervention":420,"totalTrials":489,"cells":1260},{"EARLY_PHASE1":1261,"PHASE1":1263,"PHASE2":1265,"PHASE3":1267,"PHASE4":1277,"NA":1279},{"trials":1262,"activeCount":12},[],{"trials":1264,"activeCount":12},[],{"trials":1266,"activeCount":12},[],{"trials":1268,"activeCount":489,"soonestReadout":96},[1269,1273],{"nctId":575,"briefTitle":576,"status":93,"phases":1270,"primaryCompletion":96,"completion":96,"start":578,"enrollment":579,"conditions":1271,"interventions":1272},[79],[533],[467,222,582,420,348],{"nctId":413,"briefTitle":414,"status":338,"phases":1274,"primaryCompletion":416,"completion":416,"start":341,"enrollment":417,"conditions":1275,"interventions":1276},[79],[203],[70,346,420,421],{"trials":1278,"activeCount":12},[],{"trials":1280,"activeCount":12},[],{"intervention":386,"totalTrials":489,"cells":1282},{"EARLY_PHASE1":1283,"PHASE1":1285,"PHASE2":1287,"PHASE3":1289,"PHASE4":1299,"NA":1301},{"trials":1284,"activeCount":12},[],{"trials":1286,"activeCount":12},[],{"trials":1288,"activeCount":12},[],{"trials":1290,"activeCount":489,"soonestReadout":253},[1291,1295],{"nctId":378,"briefTitle":379,"status":111,"phases":1292,"primaryCompletion":199,"completion":199,"start":381,"enrollment":382,"conditions":1293,"interventions":1294},[79],[384],[70,386,387,388,389],{"nctId":423,"briefTitle":424,"status":111,"phases":1296,"primaryCompletion":253,"completion":253,"start":426,"enrollment":427,"conditions":1297,"interventions":1298},[79],[429],[70,386,387,388,389],{"trials":1300,"activeCount":12},[],{"trials":1302,"activeCount":12},[],{"intervention":387,"totalTrials":489,"cells":1304},{"EARLY_PHASE1":1305,"PHASE1":1307,"PHASE2":1309,"PHASE3":1311,"PHASE4":1321,"NA":1323},{"trials":1306,"activeCount":12},[],{"trials":1308,"activeCount":12},[],{"trials":1310,"activeCount":12},[],{"trials":1312,"activeCount":489,"soonestReadout":253},[1313,1317],{"nctId":378,"briefTitle":379,"status":111,"phases":1314,"primaryCompletion":199,"completion":199,"start":381,"enrollment":382,"conditions":1315,"interventions":1316},[79],[384],[70,386,387,388,389],{"nctId":423,"briefTitle":424,"status":111,"phases":1318,"primaryCompletion":253,"completion":253,"start":426,"enrollment":427,"conditions":1319,"interventions":1320},[79],[429],[70,386,387,388,389],{"trials":1322,"activeCount":12},[],{"trials":1324,"activeCount":12},[],{"intervention":347,"totalTrials":646,"cells":1326},{"EARLY_PHASE1":1327,"PHASE1":1329,"PHASE2":1331,"PHASE3":1333,"PHASE4":1339,"NA":1341},{"trials":1328,"activeCount":12},[],{"trials":1330,"activeCount":12},[],{"trials":1332,"activeCount":12},[],{"trials":1334,"activeCount":646,"soonestReadout":340},[1335],{"nctId":336,"briefTitle":337,"status":338,"phases":1336,"primaryCompletion":340,"completion":340,"start":341,"enrollment":342,"conditions":1337,"interventions":1338},[78,79],[344],[70,346,347,348,349],{"trials":1340,"activeCount":12},[],{"trials":1342,"activeCount":12},[],{"intervention":573,"totalTrials":646,"cells":1344},{"EARLY_PHASE1":1345,"PHASE1":1347,"PHASE2":1349,"PHASE3":1351,"PHASE4":1357,"NA":1359},{"trials":1346,"activeCount":12},[],{"trials":1348,"activeCount":12},[],{"trials":1350,"activeCount":12},[],{"trials":1352,"activeCount":646,"soonestReadout":189},[1353],{"nctId":564,"briefTitle":565,"status":93,"phases":1354,"primaryCompletion":189,"completion":189,"start":567,"enrollment":568,"conditions":1355,"interventions":1356},[79],[570,571],[467,573],{"trials":1358,"activeCount":12},[],{"trials":1360,"activeCount":12},[],{"intervention":582,"totalTrials":646,"cells":1362},{"EARLY_PHASE1":1363,"PHASE1":1365,"PHASE2":1367,"PHASE3":1369,"PHASE4":1375,"NA":1377},{"trials":1364,"activeCount":12},[],{"trials":1366,"activeCount":12},[],{"trials":1368,"activeCount":12},[],{"trials":1370,"activeCount":646,"soonestReadout":96},[1371],{"nctId":575,"briefTitle":576,"status":93,"phases":1372,"primaryCompletion":96,"completion":96,"start":578,"enrollment":579,"conditions":1373,"interventions":1374},[79],[533],[467,222,582,420,348],{"trials":1376,"activeCount":12},[],{"trials":1378,"activeCount":12},[],{"intervention":592,"totalTrials":646,"cells":1380},{"EARLY_PHASE1":1381,"PHASE1":1383,"PHASE2":1385,"PHASE3":1387,"PHASE4":1393,"NA":1395},{"trials":1382,"activeCount":12},[],{"trials":1384,"activeCount":12},[],{"trials":1386,"activeCount":12},[],{"trials":1388,"activeCount":646,"soonestReadout":167},[1389],{"nctId":584,"briefTitle":585,"status":93,"phases":1390,"primaryCompletion":167,"completion":96,"start":587,"enrollment":588,"conditions":1391,"interventions":1392},[79],[590],[467,592],{"trials":1394,"activeCount":12},[],{"trials":1396,"activeCount":12},[],{"intervention":401,"totalTrials":646,"cells":1398},{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1405,"PHASE4":1411,"NA":1413},{"trials":1400,"activeCount":12},[],{"trials":1402,"activeCount":12},[],{"trials":1404,"activeCount":12},[],{"trials":1406,"activeCount":646,"soonestReadout":189},[1407],{"nctId":391,"briefTitle":392,"status":93,"phases":1408,"primaryCompletion":189,"completion":96,"start":394,"enrollment":395,"conditions":1409,"interventions":1410},[79],[397,398,399],[70,401],{"trials":1412,"activeCount":12},[],{"trials":1414,"activeCount":12},[],{"intervention":608,"totalTrials":646,"cells":1416},{"EARLY_PHASE1":1417,"PHASE1":1419,"PHASE2":1421,"PHASE3":1423,"PHASE4":1429,"NA":1431},{"trials":1418,"activeCount":12},[],{"trials":1420,"activeCount":12},[],{"trials":1422,"activeCount":12},[],{"trials":1424,"activeCount":646,"soonestReadout":416},[1425],{"nctId":602,"briefTitle":603,"status":338,"phases":1426,"primaryCompletion":416,"completion":416,"start":341,"enrollment":605,"conditions":1427,"interventions":1428},[79],[27],[467,500,608,376],{"trials":1430,"activeCount":12},[],{"trials":1432,"activeCount":12},[],{"intervention":616,"totalTrials":646,"cells":1434},{"EARLY_PHASE1":1435,"PHASE1":1437,"PHASE2":1439,"PHASE3":1441,"PHASE4":1447,"NA":1449},{"trials":1436,"activeCount":12},[],{"trials":1438,"activeCount":12},[],{"trials":1440,"activeCount":12},[],{"trials":1442,"activeCount":646,"soonestReadout":340},[1443],{"nctId":610,"briefTitle":611,"status":338,"phases":1444,"primaryCompletion":340,"completion":340,"start":341,"enrollment":613,"conditions":1445,"interventions":1446},[79],[397,398,399],[467,616,349,367],{"trials":1448,"activeCount":12},[],{"trials":1450,"activeCount":12},[],{"intervention":421,"totalTrials":646,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1457,"PHASE3":1459,"PHASE4":1465,"NA":1467},{"trials":1454,"activeCount":12},[],{"trials":1456,"activeCount":12},[],{"trials":1458,"activeCount":12},[],{"trials":1460,"activeCount":646,"soonestReadout":416},[1461],{"nctId":413,"briefTitle":414,"status":338,"phases":1462,"primaryCompletion":416,"completion":416,"start":341,"enrollment":417,"conditions":1463,"interventions":1464},[79],[203],[70,346,420,421],{"trials":1466,"activeCount":12},[],{"trials":1468,"activeCount":12},[],{"intervention":452,"totalTrials":646,"cells":1470},{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1477,"PHASE4":1483,"NA":1485},{"trials":1472,"activeCount":12},[],{"trials":1474,"activeCount":12},[],{"trials":1476,"activeCount":12},[],{"trials":1478,"activeCount":646,"soonestReadout":253},[1479],{"nctId":445,"briefTitle":446,"status":111,"phases":1480,"primaryCompletion":253,"completion":253,"start":448,"enrollment":449,"conditions":1481,"interventions":1482},[79],[18],[70,452],{"trials":1484,"activeCount":12},[],{"trials":1486,"activeCount":12},[],{"intervention":461,"totalTrials":646,"cells":1488},{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1501,"NA":1503},{"trials":1490,"activeCount":12},[],{"trials":1492,"activeCount":12},[],{"trials":1494,"activeCount":12},[],{"trials":1496,"activeCount":646,"soonestReadout":189},[1497],{"nctId":454,"briefTitle":455,"status":93,"phases":1498,"primaryCompletion":189,"completion":96,"start":457,"enrollment":458,"conditions":1499,"interventions":1500},[79],[36],[70,461],{"trials":1502,"activeCount":12},[],{"trials":1504,"activeCount":12},[],{"intervention":974,"totalTrials":646,"cells":1506},{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1513,"PHASE4":1519,"NA":1521},{"trials":1508,"activeCount":12},[],{"trials":1510,"activeCount":12},[],{"trials":1512,"activeCount":12},[],{"trials":1514,"activeCount":646,"soonestReadout":96},[1515],{"nctId":966,"briefTitle":967,"status":338,"phases":1516,"primaryCompletion":96,"completion":96,"start":969,"enrollment":970,"conditions":1517,"interventions":1518},[78,79],[972],[939,974,975,976,977],{"trials":1520,"activeCount":12},[],{"trials":1522,"activeCount":12},[],{"intervention":975,"totalTrials":646,"cells":1524},{"EARLY_PHASE1":1525,"PHASE1":1527,"PHASE2":1529,"PHASE3":1531,"PHASE4":1537,"NA":1539},{"trials":1526,"activeCount":12},[],{"trials":1528,"activeCount":12},[],{"trials":1530,"activeCount":12},[],{"trials":1532,"activeCount":646,"soonestReadout":96},[1533],{"nctId":966,"briefTitle":967,"status":338,"phases":1534,"primaryCompletion":96,"completion":96,"start":969,"enrollment":970,"conditions":1535,"interventions":1536},[78,79],[972],[939,974,975,976,977],{"trials":1538,"activeCount":12},[],{"trials":1540,"activeCount":12},[],{"intervention":976,"totalTrials":646,"cells":1542},{"EARLY_PHASE1":1543,"PHASE1":1545,"PHASE2":1547,"PHASE3":1549,"PHASE4":1555,"NA":1557},{"trials":1544,"activeCount":12},[],{"trials":1546,"activeCount":12},[],{"trials":1548,"activeCount":12},[],{"trials":1550,"activeCount":646,"soonestReadout":96},[1551],{"nctId":966,"briefTitle":967,"status":338,"phases":1552,"primaryCompletion":96,"completion":96,"start":969,"enrollment":970,"conditions":1553,"interventions":1554},[78,79],[972],[939,974,975,976,977],{"trials":1556,"activeCount":12},[],{"trials":1558,"activeCount":12},[],{"intervention":977,"totalTrials":646,"cells":1560},{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1567,"PHASE4":1573,"NA":1575},{"trials":1562,"activeCount":12},[],{"trials":1564,"activeCount":12},[],{"trials":1566,"activeCount":12},[],{"trials":1568,"activeCount":646,"soonestReadout":96},[1569],{"nctId":966,"briefTitle":967,"status":338,"phases":1570,"primaryCompletion":96,"completion":96,"start":969,"enrollment":970,"conditions":1571,"interventions":1572},[78,79],[972],[939,974,975,976,977],{"trials":1574,"activeCount":12},[],{"trials":1576,"activeCount":12},[],{"intervention":50,"totalTrials":633,"cells":1578},{"EARLY_PHASE1":1579,"PHASE1":1581,"PHASE2":1588,"PHASE3":1630,"PHASE4":1632,"NA":1634},{"trials":1580,"activeCount":12},[],{"trials":1582,"activeCount":646,"soonestReadout":41},[1583],{"nctId":48,"briefTitle":49,"status":111,"phases":1584,"primaryCompletion":41,"completion":41,"start":1585,"enrollment":642,"conditions":1586,"interventions":1587},[77],"2020-11-10",[15],[50],{"trials":1589,"activeCount":22,"soonestReadout":327},[1590,1594,1598,1602,1606,1610,1614,1618,1622,1626],{"nctId":130,"briefTitle":131,"status":93,"phases":1591,"primaryCompletion":95,"completion":96,"start":133,"enrollment":134,"conditions":1592,"interventions":1593},[78],[36,15],[70,50],{"nctId":138,"briefTitle":139,"status":93,"phases":1595,"primaryCompletion":95,"completion":96,"start":141,"enrollment":142,"conditions":1596,"interventions":1597},[78],[24],[70,50],{"nctId":156,"briefTitle":157,"status":93,"phases":1599,"primaryCompletion":95,"completion":96,"start":159,"enrollment":160,"conditions":1600,"interventions":1601},[78],[18,33],[70,50],{"nctId":175,"briefTitle":176,"status":93,"phases":1603,"primaryCompletion":95,"completion":96,"start":178,"enrollment":179,"conditions":1604,"interventions":1605},[78],[181,182,183],[50,70,154],{"nctId":670,"briefTitle":671,"status":93,"phases":1607,"primaryCompletion":327,"completion":327,"start":673,"enrollment":642,"conditions":1608,"interventions":1609},[78],[24],[42,50],{"nctId":225,"briefTitle":226,"status":93,"phases":1611,"primaryCompletion":95,"completion":96,"start":228,"enrollment":229,"conditions":1612,"interventions":1613},[78],[21],[70,50],{"nctId":269,"briefTitle":270,"status":93,"phases":1615,"primaryCompletion":95,"completion":96,"start":272,"enrollment":273,"conditions":1616,"interventions":1617},[78],[219],[70,50],{"nctId":677,"briefTitle":678,"status":93,"phases":1619,"primaryCompletion":95,"completion":96,"start":680,"enrollment":681,"conditions":1620,"interventions":1621},[77,78],[18],[42,50],{"nctId":304,"briefTitle":305,"status":93,"phases":1623,"primaryCompletion":95,"completion":96,"start":307,"enrollment":308,"conditions":1624,"interventions":1625},[78],[310],[70,50],{"nctId":692,"briefTitle":693,"status":93,"phases":1627,"primaryCompletion":95,"completion":96,"start":695,"enrollment":273,"conditions":1628,"interventions":1629},[77,78],[697],[42,50],{"trials":1631,"activeCount":12},[],{"trials":1633,"activeCount":12},[],{"trials":1635,"activeCount":12},[],{"intervention":46,"totalTrials":25,"cells":1637},{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1669,"PHASE3":1704,"PHASE4":1706,"NA":1708},{"trials":1639,"activeCount":12},[],{"trials":1641,"activeCount":34,"soonestReadout":41},[1642,1651,1659],{"nctId":1643,"briefTitle":1644,"status":93,"phases":1645,"primaryCompletion":96,"completion":96,"start":1646,"enrollment":1647,"conditions":1648,"interventions":1650},"NCT06857227","A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis",[77],"2025-03-17",54,[1649],"Rheumatoid Arthritis",[46],{"nctId":1652,"briefTitle":1653,"status":93,"phases":1654,"primaryCompletion":96,"completion":96,"start":1655,"enrollment":1647,"conditions":1656,"interventions":1658},"NCT06857214","A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus Erythematosus",[77],"2025-06-04",[1657],"Systemic Lupus Erythematosus",[46],{"nctId":1660,"briefTitle":1661,"status":111,"phases":1662,"primaryCompletion":41,"completion":41,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1668},"NCT04606433","Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia",[77],"2020-11-04",47,[1666,1667],"Non Hodgkin Lymphoma","Acute Lymphoblastic Leukemia",[46],{"trials":1670,"activeCount":31,"soonestReadout":41},[1671,1679,1687,1695],{"nctId":44,"briefTitle":45,"status":111,"phases":1672,"primaryCompletion":41,"completion":41,"start":1673,"enrollment":31,"conditions":1674,"interventions":1678},[77,78],"2023-02-21",[1675,1676,1677],"NK\u002FT Cell Lymphoma","Vascular Immunomother T Cell Lymphoma","Non-Hodgkin Lymphoma",[46],{"nctId":1680,"briefTitle":1681,"status":111,"phases":1682,"primaryCompletion":41,"completion":41,"start":695,"enrollment":25,"conditions":1683,"interventions":1686},"NCT05485753","A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)",[77,78],[1684,1685],"Primary Central Nervous System Lymphoma","Secondary Central Nervous System Lymphoma",[46],{"nctId":1688,"briefTitle":1689,"status":93,"phases":1690,"primaryCompletion":95,"completion":96,"start":1691,"enrollment":300,"conditions":1692,"interventions":1694},"NCT05623982","A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma",[77,78],"2022-09-26",[1693],"Non-hodgkin's Lymphoma",[46],{"nctId":1696,"briefTitle":1697,"status":111,"phases":1698,"primaryCompletion":41,"completion":41,"start":1699,"enrollment":1700,"conditions":1701,"interventions":1703},"NCT05192486","A Study of GNC-038, a Tetra-specific Antibody, in Participants With R\u002FR Diffuse Large B-cell Lymphoma (DLBCL)",[77,78],"2022-08-10",12,[1702],"Diffuse Large B-cell Lymphoma",[46],{"trials":1705,"activeCount":12},[],{"trials":1707,"activeCount":12},[],{"trials":1709,"activeCount":12},[],{"intervention":154,"totalTrials":544,"cells":1711},{"EARLY_PHASE1":1712,"PHASE1":1714,"PHASE2":1716,"PHASE3":1742,"PHASE4":1744,"NA":1746},{"trials":1713,"activeCount":12},[],{"trials":1715,"activeCount":12},[],{"trials":1717,"activeCount":544,"soonestReadout":199},[1718,1722,1726,1730,1734,1738],{"nctId":146,"briefTitle":147,"status":93,"phases":1719,"primaryCompletion":149,"completion":149,"start":150,"enrollment":134,"conditions":1720,"interventions":1721},[78],[152],[70,154],{"nctId":175,"briefTitle":176,"status":93,"phases":1723,"primaryCompletion":95,"completion":96,"start":178,"enrollment":179,"conditions":1724,"interventions":1725},[78],[181,182,183],[50,70,154],{"nctId":196,"briefTitle":197,"status":93,"phases":1727,"primaryCompletion":199,"completion":199,"start":200,"enrollment":201,"conditions":1728,"interventions":1729},[78],[203],[70,205],{"nctId":502,"briefTitle":503,"status":93,"phases":1731,"primaryCompletion":505,"completion":505,"start":506,"enrollment":300,"conditions":1732,"interventions":1733},[78],[508],[467,205],{"nctId":207,"briefTitle":208,"status":93,"phases":1735,"primaryCompletion":199,"completion":199,"start":210,"enrollment":169,"conditions":1736,"interventions":1737},[78],[24],[70,205],{"nctId":313,"briefTitle":314,"status":93,"phases":1739,"primaryCompletion":149,"completion":149,"start":316,"enrollment":98,"conditions":1740,"interventions":1741},[78],[18,33,15],[70,154,319],{"trials":1743,"activeCount":12},[],{"trials":1745,"activeCount":12},[],{"trials":1747,"activeCount":12},[],{"intervention":63,"totalTrials":28,"cells":1749},{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1779,"PHASE3":1794,"PHASE4":1796,"NA":1798},{"trials":1751,"activeCount":12},[],{"trials":1753,"activeCount":489,"soonestReadout":41},[1754,1761,1770],{"nctId":1755,"briefTitle":1756,"status":111,"phases":1757,"primaryCompletion":41,"completion":41,"start":1758,"enrollment":107,"conditions":1759,"interventions":1760},"NCT05160545","A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer",[77],"2021-11-26",[21],[63],{"nctId":1762,"briefTitle":1763,"status":111,"phases":1764,"primaryCompletion":41,"completion":41,"start":1765,"enrollment":1766,"conditions":1767,"interventions":1769},"NCT05104775","A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed\u002FRefractory Hematologic Malignancy",[77],"2022-02-09",33,[1768],"Hematologic Malignancies",[63],{"nctId":1771,"briefTitle":1772,"status":1773,"phases":1774,"primaryCompletion":1775,"completion":1775,"start":1776,"enrollment":12,"conditions":1777,"interventions":1778},"NCT05039931","A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors","WITHDRAWN",[77],"2023-06","2021-09-15",[21,15],[63],{"trials":1780,"activeCount":489,"soonestReadout":41},[1781,1788],{"nctId":1782,"briefTitle":1783,"status":93,"phases":1784,"primaryCompletion":95,"completion":96,"start":1785,"enrollment":300,"conditions":1786,"interventions":1787},"NCT06066203","A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies",[77,78],"2023-11-01",[1693],[63],{"nctId":61,"briefTitle":62,"status":111,"phases":1789,"primaryCompletion":41,"completion":41,"start":1790,"enrollment":34,"conditions":1791,"interventions":1793},[77,78],"2023-08-16",[1792],"Relapsed\u002FRefractory Chronic Lymphocytic Leukemia",[63],{"trials":1795,"activeCount":12},[],{"trials":1797,"activeCount":12},[],{"trials":1799,"activeCount":12},[],{"intervention":74,"totalTrials":34,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1821,"PHASE3":1828,"PHASE4":1830,"NA":1832},{"trials":1803,"activeCount":12},[],{"trials":1805,"activeCount":489,"soonestReadout":41},[1806,1814],{"nctId":1807,"briefTitle":1808,"status":111,"phases":1809,"primaryCompletion":41,"completion":41,"start":1810,"enrollment":1811,"conditions":1812,"interventions":1813},"NCT05339685","A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors",[77],"2022-05-20",82,[21],[74],{"nctId":1815,"briefTitle":1816,"status":111,"phases":1817,"primaryCompletion":41,"completion":41,"start":1818,"enrollment":665,"conditions":1819,"interventions":1820},"NCT05385692","A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors",[77],"2022-06-01",[480,15],[74],{"trials":1822,"activeCount":646,"soonestReadout":41},[1823],{"nctId":72,"briefTitle":73,"status":111,"phases":1824,"primaryCompletion":41,"completion":41,"start":1825,"enrollment":725,"conditions":1826,"interventions":1827},[77,78],"2023-09-04",[18],[74],{"trials":1829,"activeCount":12},[],{"trials":1831,"activeCount":12},[],{"trials":1833,"activeCount":12},[],{"intervention":173,"totalTrials":489,"cells":1835},{"EARLY_PHASE1":1836,"PHASE1":1838,"PHASE2":1840,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1837,"activeCount":12},[],{"trials":1839,"activeCount":12},[],{"trials":1841,"activeCount":489,"soonestReadout":167},[1842,1846],{"nctId":164,"briefTitle":165,"status":93,"phases":1843,"primaryCompletion":167,"completion":96,"start":168,"enrollment":169,"conditions":1844,"interventions":1845},[78],[171],[70,173],{"nctId":277,"briefTitle":278,"status":93,"phases":1847,"primaryCompletion":167,"completion":96,"start":280,"enrollment":281,"conditions":1848,"interventions":1849},[78],[283],[70,285,173,222],{"trials":1851,"activeCount":12},[],{"trials":1853,"activeCount":12},[],{"trials":1855,"activeCount":12},[],{"intervention":267,"totalTrials":489,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1872,"PHASE4":1874,"NA":1876},{"trials":1859,"activeCount":12},[],{"trials":1861,"activeCount":12},[],{"trials":1863,"activeCount":489,"soonestReadout":298},[1864,1868],{"nctId":259,"briefTitle":260,"status":111,"phases":1865,"primaryCompletion":262,"completion":262,"start":263,"enrollment":264,"conditions":1866,"interventions":1867},[78],[18],[70,267],{"nctId":295,"briefTitle":296,"status":93,"phases":1869,"primaryCompletion":298,"completion":298,"start":299,"enrollment":300,"conditions":1870,"interventions":1871},[78],[18],[70,267],{"trials":1873,"activeCount":12},[],{"trials":1875,"activeCount":12},[],{"trials":1877,"activeCount":12},[],{"intervention":656,"totalTrials":646,"cells":1879},{"EARLY_PHASE1":1880,"PHASE1":1882,"PHASE2":1884,"PHASE3":1890,"PHASE4":1892,"NA":1894},{"trials":1881,"activeCount":12},[],{"trials":1883,"activeCount":12},[],{"trials":1885,"activeCount":646,"soonestReadout":41},[1886],{"nctId":39,"briefTitle":40,"status":111,"phases":1887,"primaryCompletion":41,"completion":41,"start":651,"enrollment":652,"conditions":1888,"interventions":1889},[78],[654],[42,656,376],{"trials":1891,"activeCount":12},[],{"trials":1893,"activeCount":12},[],{"trials":1895,"activeCount":12},[],{"intervention":223,"totalTrials":646,"cells":1897},{"EARLY_PHASE1":1898,"PHASE1":1900,"PHASE2":1902,"PHASE3":1908,"PHASE4":1910,"NA":1912},{"trials":1899,"activeCount":12},[],{"trials":1901,"activeCount":12},[],{"trials":1903,"activeCount":646,"soonestReadout":167},[1904],{"nctId":214,"briefTitle":215,"status":93,"phases":1905,"primaryCompletion":167,"completion":96,"start":217,"enrollment":123,"conditions":1906,"interventions":1907},[78],[219,220],[70,222,223],{"trials":1909,"activeCount":12},[],{"trials":1911,"activeCount":12},[],{"trials":1913,"activeCount":12},[],{"intervention":257,"totalTrials":646,"cells":1915},{"EARLY_PHASE1":1916,"PHASE1":1918,"PHASE2":1920,"PHASE3":1926,"PHASE4":1928,"NA":1930},{"trials":1917,"activeCount":12},[],{"trials":1919,"activeCount":12},[],{"trials":1921,"activeCount":646,"soonestReadout":253},[1922],{"nctId":250,"briefTitle":251,"status":93,"phases":1923,"primaryCompletion":253,"completion":253,"start":254,"enrollment":134,"conditions":1924,"interventions":1925},[78],[36],[70,257],{"trials":1927,"activeCount":12},[],{"trials":1929,"activeCount":12},[],{"trials":1931,"activeCount":12},[],{"intervention":285,"totalTrials":646,"cells":1933},{"EARLY_PHASE1":1934,"PHASE1":1936,"PHASE2":1938,"PHASE3":1944,"PHASE4":1946,"NA":1948},{"trials":1935,"activeCount":12},[],{"trials":1937,"activeCount":12},[],{"trials":1939,"activeCount":646,"soonestReadout":167},[1940],{"nctId":277,"briefTitle":278,"status":93,"phases":1941,"primaryCompletion":167,"completion":96,"start":280,"enrollment":281,"conditions":1942,"interventions":1943},[78],[283],[70,285,173,222],{"trials":1945,"activeCount":12},[],{"trials":1947,"activeCount":12},[],{"trials":1949,"activeCount":12},[],{"intervention":1951,"totalTrials":646,"cells":1952},"BL-B01D1 for",{"EARLY_PHASE1":1953,"PHASE1":1955,"PHASE2":1957,"PHASE3":1968,"PHASE4":1970,"NA":1972},{"trials":1954,"activeCount":12},[],{"trials":1956,"activeCount":12},[],{"trials":1958,"activeCount":646,"soonestReadout":505},[1959],{"nctId":1960,"briefTitle":1961,"status":93,"phases":1962,"primaryCompletion":505,"completion":505,"start":1963,"enrollment":1964,"conditions":1965,"interventions":1967},"NCT06598787","A Study of BL-B01D1 in Patients With Recurrent Glioblastoma",[78],"2024-10-17",20,[1966],"Recurrent Glioblastoma",[1951],{"trials":1969,"activeCount":12},[],{"trials":1971,"activeCount":12},[],{"trials":1973,"activeCount":12},[],{"intervention":319,"totalTrials":646,"cells":1975},{"EARLY_PHASE1":1976,"PHASE1":1978,"PHASE2":1980,"PHASE3":1986,"PHASE4":1988,"NA":1990},{"trials":1977,"activeCount":12},[],{"trials":1979,"activeCount":12},[],{"trials":1981,"activeCount":646,"soonestReadout":149},[1982],{"nctId":313,"briefTitle":314,"status":93,"phases":1983,"primaryCompletion":149,"completion":149,"start":316,"enrollment":98,"conditions":1984,"interventions":1985},[78],[18,33,15],[70,154,319],{"trials":1987,"activeCount":12},[],{"trials":1989,"activeCount":12},[],{"trials":1991,"activeCount":12},[],{"intervention":1993,"totalTrials":31,"cells":1994},"BL-M24D1",{"EARLY_PHASE1":1995,"PHASE1":1997,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":1996,"activeCount":12},[],{"trials":1998,"activeCount":31,"soonestReadout":2018},[1999,2006,2014,2023],{"nctId":2000,"briefTitle":2001,"status":338,"phases":2002,"primaryCompletion":96,"completion":96,"start":41,"enrollment":1766,"conditions":2003,"interventions":2005},"NCT07255898","A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies",[77],[2004,1768],"Multiple Myeloma",[1993],{"nctId":2007,"briefTitle":2008,"status":93,"phases":2009,"primaryCompletion":96,"completion":96,"start":2010,"enrollment":1766,"conditions":2011,"interventions":2013},"NCT07279428","A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors",[77],"2026-01-12",[2012,30],"Gastrointestinal Tumors",[1993],{"nctId":2015,"briefTitle":2016,"status":93,"phases":2017,"primaryCompletion":2018,"completion":2018,"start":2019,"enrollment":2020,"conditions":2021,"interventions":2022},"NCT07232524","A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",[77],"2027-11","2025-12-10",16,[24,15],[1993],{"nctId":2024,"briefTitle":2025,"status":93,"phases":2026,"primaryCompletion":96,"completion":96,"start":2027,"enrollment":1766,"conditions":2028,"interventions":2029},"NCT07232420","A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors",[77],"2025-11-11",[654,15],[1993],{"trials":2031,"activeCount":12},[],{"trials":2033,"activeCount":12},[],{"trials":2035,"activeCount":12},[],{"trials":2037,"activeCount":12},[],{"intervention":2039,"totalTrials":34,"cells":2040},"GNC-077",{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2066,"PHASE3":2068,"PHASE4":2070,"NA":2072},{"trials":2042,"activeCount":12},[],{"trials":2044,"activeCount":34,"soonestReadout":505},[2045,2052,2059],{"nctId":2046,"briefTitle":2047,"status":93,"phases":2048,"primaryCompletion":505,"completion":505,"start":2049,"enrollment":1964,"conditions":2050,"interventions":2051},"NCT06609187","A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",[77],"2024-10-30",[21,15],[2039],{"nctId":2053,"briefTitle":2054,"status":338,"phases":2055,"primaryCompletion":189,"completion":96,"start":2056,"enrollment":1964,"conditions":2057,"interventions":2058},"NCT06755242","A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors",[77],"2025-01",[2012,15],[2039],{"nctId":2060,"briefTitle":2061,"status":93,"phases":2062,"primaryCompletion":505,"completion":505,"start":2063,"enrollment":1964,"conditions":2064,"interventions":2065},"NCT06612840","A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors",[77],"2024-10-16",[18,15],[2039],{"trials":2067,"activeCount":12},[],{"trials":2069,"activeCount":12},[],{"trials":2071,"activeCount":12},[],{"trials":2073,"activeCount":12},[],{"intervention":2075,"totalTrials":34,"cells":2076},"BL-B16D1",{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2103,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2078,"activeCount":12},[],{"trials":2080,"activeCount":34,"soonestReadout":149},[2081,2089,2096],{"nctId":2082,"briefTitle":2083,"status":93,"phases":2084,"primaryCompletion":149,"completion":149,"start":2085,"enrollment":320,"conditions":2086,"interventions":2088},"NCT06469008","A Study of BL-B16D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",[77],"2024-06-27",[2087,15],"Head and Neck Squamous Cell Carcinomas",[2075],{"nctId":2090,"briefTitle":2091,"status":93,"phases":2092,"primaryCompletion":149,"completion":149,"start":2093,"enrollment":320,"conditions":2094,"interventions":2095},"NCT06493864","A Study of BL-B16D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors",[77],"2024-08-26",[21,15],[2075],{"nctId":2097,"briefTitle":2098,"status":93,"phases":2099,"primaryCompletion":149,"completion":149,"start":2100,"enrollment":320,"conditions":2101,"interventions":2102},"NCT06475131","A Study of BL-B16D1 in Patients With Locally Advanced or Metastatic Solid Tumors",[77],"2024-07-18",[15],[2075],{"trials":2104,"activeCount":12},[],{"trials":2106,"activeCount":12},[],{"trials":2108,"activeCount":12},[],{"trials":2110,"activeCount":12},[],{"intervention":2112,"totalTrials":489,"cells":2113},"BL-M09D1",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2133,"PHASE3":2135,"PHASE4":2137,"NA":2139},{"trials":2115,"activeCount":12},[],{"trials":2117,"activeCount":489,"soonestReadout":167},[2118,2125],{"nctId":2119,"briefTitle":2120,"status":93,"phases":2121,"primaryCompletion":167,"completion":96,"start":587,"enrollment":2122,"conditions":2123,"interventions":2124},"NCT06954077","A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors",[77],45,[125,15],[2112],{"nctId":2126,"briefTitle":2127,"status":93,"phases":2128,"primaryCompletion":96,"completion":96,"start":2129,"enrollment":2130,"conditions":2131,"interventions":2132},"NCT07056556","A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors",[77],"2025-07-30",31,[18,15],[2112],{"trials":2134,"activeCount":12},[],{"trials":2136,"activeCount":12},[],{"trials":2138,"activeCount":12},[],{"trials":2140,"activeCount":12},[],{"intervention":2142,"totalTrials":489,"cells":2143},"BL-M17D1",{"EARLY_PHASE1":2144,"PHASE1":2146,"PHASE2":2163,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2145,"activeCount":12},[],{"trials":2147,"activeCount":489,"soonestReadout":298},[2148,2156],{"nctId":2149,"briefTitle":2150,"status":93,"phases":2151,"primaryCompletion":298,"completion":298,"start":2152,"enrollment":1964,"conditions":2153,"interventions":2155},"NCT06500052","A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive\u002FLower Expression Gastrointestinal Cancer and Other Solid Tumors",[77],"2024-07-24",[181,182,2154,183,15],"Pancreatic Cancer",[2142],{"nctId":2157,"briefTitle":2158,"status":93,"phases":2159,"primaryCompletion":298,"completion":298,"start":2160,"enrollment":1964,"conditions":2161,"interventions":2162},"NCT06503783","A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive\u002FNegative Breast Cancer and Other Solid Tumors",[77],"2024-08-24",[21,15],[2142],{"trials":2164,"activeCount":12},[],{"trials":2166,"activeCount":12},[],{"trials":2168,"activeCount":12},[],{"trials":2170,"activeCount":12},[],{"intervention":2172,"totalTrials":489,"cells":2173},"Lutetium [177Lu] BL-ARC001",{"EARLY_PHASE1":2174,"PHASE1":2176,"PHASE2":2192,"PHASE3":2194,"PHASE4":2196,"NA":2198},{"trials":2175,"activeCount":12},[],{"trials":2177,"activeCount":489,"soonestReadout":96},[2178,2185],{"nctId":2179,"briefTitle":2180,"status":93,"phases":2181,"primaryCompletion":96,"completion":96,"start":2019,"enrollment":665,"conditions":2182,"interventions":2184},"NCT07274852","A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors",[77],[2183,21,24,30],"Lung Cancer",[2172],{"nctId":2186,"briefTitle":2187,"status":93,"phases":2188,"primaryCompletion":96,"completion":96,"start":2189,"enrollment":665,"conditions":2190,"interventions":2191},"NCT07232407","A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors",[77],"2025-11-14",[2012,30],[2172],{"trials":2193,"activeCount":12},[],{"trials":2195,"activeCount":12},[],{"trials":2197,"activeCount":12},[],{"trials":2199,"activeCount":12},[],{"intervention":2201,"totalTrials":489,"cells":2202},"BL-M08D1",{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2222,"PHASE3":2224,"PHASE4":2226,"NA":2228},{"trials":2204,"activeCount":12},[],{"trials":2206,"activeCount":489,"soonestReadout":95},[2207,2214],{"nctId":2208,"briefTitle":2209,"status":93,"phases":2210,"primaryCompletion":95,"completion":189,"start":2211,"enrollment":665,"conditions":2212,"interventions":2213},"NCT06718621","A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors",[77],"2025-02-12",[15],[2201],{"nctId":2215,"briefTitle":2216,"status":93,"phases":2217,"primaryCompletion":189,"completion":96,"start":2218,"enrollment":665,"conditions":2219,"interventions":2221},"NCT06718634","A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies",[77],"2025-01-02",[2220],"Relapsed or Refractory Lymphoid Malignancies",[2201],{"trials":2223,"activeCount":12},[],{"trials":2225,"activeCount":12},[],{"trials":2227,"activeCount":12},[],{"trials":2229,"activeCount":12},[],{"intervention":2231,"totalTrials":646,"cells":2232},"BL-ARC002",{"EARLY_PHASE1":2233,"PHASE1":2235,"PHASE2":2244,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2234,"activeCount":12},[],{"trials":2236,"activeCount":646,"soonestReadout":96},[2237],{"nctId":2238,"briefTitle":2239,"status":93,"phases":2240,"primaryCompletion":96,"completion":96,"start":2241,"enrollment":665,"conditions":2242,"interventions":2243},"NCT07591155","A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid Tumors",[77],"2026-05-13",[30],[2231],{"trials":2245,"activeCount":12},[],{"trials":2247,"activeCount":12},[],{"trials":2249,"activeCount":12},[],{"trials":2251,"activeCount":12},[],{"intervention":2253,"totalTrials":646,"cells":2254},"SI-B036",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2265,"PHASE3":2267,"PHASE4":2269,"NA":2271},{"trials":2256,"activeCount":12},[],{"trials":2258,"activeCount":646,"soonestReadout":340},[2259],{"nctId":2260,"briefTitle":2261,"status":338,"phases":2262,"primaryCompletion":340,"completion":340,"start":253,"enrollment":2130,"conditions":2263,"interventions":2264},"NCT07606612","A Study of SI-B036 in Patients With Locally Advanced or Metastatic Solid Tumors",[77],[15],[2253],{"trials":2266,"activeCount":12},[],{"trials":2268,"activeCount":12},[],{"trials":2270,"activeCount":12},[],{"trials":2272,"activeCount":12},[],{"intervention":2274,"totalTrials":646,"cells":2275},"GNC-039",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2288,"PHASE3":2290,"PHASE4":2292,"NA":2294},{"trials":2277,"activeCount":12},[],{"trials":2279,"activeCount":646,"soonestReadout":41},[2280],{"nctId":2281,"briefTitle":2282,"status":93,"phases":2283,"primaryCompletion":41,"completion":95,"start":2284,"enrollment":642,"conditions":2285,"interventions":2287},"NCT04794972","A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed\u002FRefractory or Metastatic Solid Tumors",[77],"2021-04-14",[2286,15],"Recurrent Glioma",[2274],{"trials":2289,"activeCount":12},[],{"trials":2291,"activeCount":12},[],{"trials":2293,"activeCount":12},[],{"trials":2295,"activeCount":12},[],{"intervention":2297,"totalTrials":646,"cells":2298},"BL-M14D1",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2310,"PHASE3":2312,"PHASE4":2314,"NA":2316},{"trials":2300,"activeCount":12},[],{"trials":2302,"activeCount":646,"soonestReadout":298},[2303],{"nctId":2304,"briefTitle":2305,"status":93,"phases":2306,"primaryCompletion":298,"completion":298,"start":150,"enrollment":665,"conditions":2307,"interventions":2309},"NCT06505824","A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors",[77],[310,2308],"Neuroendocrine Tumors",[2297],{"trials":2311,"activeCount":12},[],{"trials":2313,"activeCount":12},[],{"trials":2315,"activeCount":12},[],{"trials":2317,"activeCount":12},[],{"intervention":2319,"totalTrials":646,"cells":2320},"Amiodarone",{"EARLY_PHASE1":2321,"PHASE1":2323,"PHASE2":2325,"PHASE3":2327,"PHASE4":2329,"NA":2344},{"trials":2322,"activeCount":12},[],{"trials":2324,"activeCount":12},[],{"trials":2326,"activeCount":12},[],{"trials":2328,"activeCount":12},[],{"trials":2330,"activeCount":12},[2331],{"nctId":2332,"briefTitle":2333,"status":2334,"phases":2335,"primaryCompletion":2336,"completion":2336,"start":2337,"enrollment":2338,"conditions":2339,"interventions":2342},"NCT03855826","Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.","UNKNOWN",[80],"2020-01-30","2019-01-15",756,[2340,2341],"Ventricular Tachycardia","Ventricular Fibrillation",[2343,2319],"Nifekalant hydrochloride",{"trials":2345,"activeCount":12},[],{"intervention":708,"totalTrials":646,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2358,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":12},[],{"trials":2351,"activeCount":12},[],{"trials":2353,"activeCount":12},[2354],{"nctId":700,"briefTitle":701,"status":702,"phases":2355,"primaryCompletion":704,"completion":704,"start":705,"enrollment":25,"conditions":2356,"interventions":2357},[78],[183],[42,410,708,709],{"trials":2359,"activeCount":12},[],{"trials":2361,"activeCount":12},[],{"trials":2363,"activeCount":12},[],{"intervention":709,"totalTrials":646,"cells":2365},{"EARLY_PHASE1":2366,"PHASE1":2368,"PHASE2":2370,"PHASE3":2376,"PHASE4":2378,"NA":2380},{"trials":2367,"activeCount":12},[],{"trials":2369,"activeCount":12},[],{"trials":2371,"activeCount":12},[2372],{"nctId":700,"briefTitle":701,"status":702,"phases":2373,"primaryCompletion":704,"completion":704,"start":705,"enrollment":25,"conditions":2374,"interventions":2375},[78],[183],[42,410,708,709],{"trials":2377,"activeCount":12},[],{"trials":2379,"activeCount":12},[],{"trials":2381,"activeCount":12},[],{"intervention":2383,"totalTrials":646,"cells":2384},"SI-F019",{"EARLY_PHASE1":2385,"PHASE1":2387,"PHASE2":2399,"PHASE3":2401,"PHASE4":2403,"NA":2405},{"trials":2386,"activeCount":12},[],{"trials":2388,"activeCount":12},[2389],{"nctId":2390,"briefTitle":2391,"status":2392,"phases":2393,"primaryCompletion":2394,"completion":2394,"start":2395,"enrollment":107,"conditions":2396,"interventions":2398},"NCT04851444","A Study of SI-F019 in Healthy Participants","COMPLETED",[77],"2021-09-20","2021-03-30",[2397],"Healthy",[2383],{"trials":2400,"activeCount":12},[],{"trials":2402,"activeCount":12},[],{"trials":2404,"activeCount":12},[],{"trials":2406,"activeCount":12},[],{"intervention":2343,"totalTrials":489,"cells":2408},{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2417,"NA":2423},{"trials":2410,"activeCount":12},[],{"trials":2412,"activeCount":12},[],{"trials":2414,"activeCount":12},[],{"trials":2416,"activeCount":12},[],{"trials":2418,"activeCount":12},[2419],{"nctId":2332,"briefTitle":2333,"status":2334,"phases":2420,"primaryCompletion":2336,"completion":2336,"start":2337,"enrollment":2338,"conditions":2421,"interventions":2422},[80],[2340,2341],[2343,2319],{"trials":2424,"activeCount":12},[2425],{"nctId":2426,"briefTitle":2427,"status":2334,"phases":2428,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":2431,"conditions":2432,"interventions":2433},"NCT03853369","Post-marketing Registration Study of Nifekalant Hydrochloride (NIF) Injection",[],"2019-12-30","2019-02-18",2000,[2340,2341],[2343]]